HRP20192311T4 - Adam6 miševi - Google Patents

Adam6 miševi Download PDF

Info

Publication number
HRP20192311T4
HRP20192311T4 HRP20192311TT HRP20192311T HRP20192311T4 HR P20192311 T4 HRP20192311 T4 HR P20192311T4 HR P20192311T T HRP20192311T T HR P20192311TT HR P20192311 T HRP20192311 T HR P20192311T HR P20192311 T4 HRP20192311 T4 HR P20192311T4
Authority
HR
Croatia
Prior art keywords
ortholog
fragment
mouse
protein
nucleic acid
Prior art date
Application number
HRP20192311TT
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192311(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20192311T1 publication Critical patent/HRP20192311T1/hr
Publication of HRP20192311T4 publication Critical patent/HRP20192311T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (6)

1. Genetički modificirani miš čiji genom sadrži : (a) ektopičnu sekvencu nukleinske kiseline koja kodira mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, gdje mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment su eksprimirani iz ektopične sekvence nukleinske kiseline; i (b) varijabilnu regiju lokusa teškog lanca humaniziranog imunoglobulina koji sadrži modifikaciju koja smanjuje ili uklanja endogenu funkciju ADAM6 u muškom mišu, gdje je ektopična sekvenca nukleinske kiseline prisutna u okviru varijabilne regije lokusa humaniziranog teškog lanca.
2. Miš prema zahtjevu 1, gdje varijabilna regija lokusa teškog lanca humaniziranog imunoglobulina obuhvaća umetanje jednog ili više humanih segmenata VH gena, jedan ili više humanih segmenata DH gena, i jedan ili više humanih segmenata JH gena.
3. Izolirana mišja stanica čiji genom sadrži : (a) ektopičnu sekvencu nukleinske kiseline koja sadrži sekvencu koja kodira mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, gdje mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment su eksprimirani iz ektopične sekvence nukleinske kiseline; i b) varijabilna regija lokusa teškog lanca humaniziranog imunoglobulina koji sadrži modifikaciju koja smanjuje ili uklanja endogenu funkciju ADAM6 u muškom mišu, gdje je ektopična sekvenca nukleinske kiseline prisutna u okviru varijabilne regije lokusa humaniziranog teškog lanca.
4. Imortalizirana stanična linija napravljena od izolirane stanice prema zahtjevu 3, gdje genom spomenute imortalizirane stanične linije sadrži: (a) ektopičnu sekvencu nukleinske kiseline koja sadrži sekvencu koja kodira mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, gdje mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment su eksprimovani iz ektopične sekvence nukleinske kiseline; i b) varijabilnu regiju lokusa teškog lanca humaniziranog imunoglobulina koja sadrži modifikaciju koja smanjuje ili uklanja endogenu funkciju ADAM6 u muškom mišu, gdje je ektopična sekvenca nukleinske kiseline prisutna u okviru varijabilne regije lokusa humaniziranog teškog lanca.
5. Izolirana stanica prema zahtjevu 3, gdje je stanica mišja embrionska stem stanica.
6. Mišji embrij čiji genom sadrži : (a) ektopičnu sekvencu nukleinske kiseline koja sadrži sekvencu koja kodira mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment koji je funkcionalan u muškom mišu, gdje mišji ADAM6a protein ili njegov ortolog ili homolog ili fragment i mišji ADAM6b protein ili njegov ortolog ili homolog ili fragment su eksprimirani iz ektopične sekvence nukleinske kiseline; i b) varijabilnu regiju lokusa teškog lanca humaniziranog imunoglobulina koja sadrži modifikaciju koja smanjuje ili uklanja endogenu funkciju ADAM6 u muškom mišu, gdje je ektopična sekvenca nukleinske kiseline prisutna u okviru varijabilne regije lokusa humaniziranog teškog lanca.
HRP20192311TT 2011-02-25 2012-02-24 Adam6 miševi HRP20192311T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP14154918.8A EP2738258B2 (en) 2011-02-25 2012-02-24 ADAM6 mice

Publications (2)

Publication Number Publication Date
HRP20192311T1 HRP20192311T1 (hr) 2020-03-20
HRP20192311T4 true HRP20192311T4 (hr) 2023-05-12

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20191895TT HRP20191895T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20230526TT HRP20230526T1 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20192311TT HRP20192311T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20150262AT HRP20150262T1 (hr) 2011-02-25 2015-03-09 Miševi sa adam6
HRP20200294TT HRP20200294T1 (hr) 2011-02-25 2020-02-21 Miševi s adam6

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HRP20191895TT HRP20191895T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20230526TT HRP20230526T1 (hr) 2011-02-25 2012-02-24 Adam6 miševi

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20150262AT HRP20150262T1 (hr) 2011-02-25 2015-03-09 Miševi sa adam6
HRP20200294TT HRP20200294T1 (hr) 2011-02-25 2020-02-21 Miševi s adam6

Country Status (32)

Country Link
US (11) US8642835B2 (hr)
EP (7) EP2738259B1 (hr)
JP (7) JP2014507137A (hr)
KR (1) KR101387377B1 (hr)
CN (2) CN105861548B (hr)
AU (5) AU2012243291B2 (hr)
BR (1) BR112013021771B1 (hr)
CA (1) CA2820824A1 (hr)
CY (5) CY1116301T1 (hr)
DE (5) DE12192727T1 (hr)
DK (6) DK2550363T3 (hr)
ES (6) ES2770424T3 (hr)
FI (3) FI2738258T4 (hr)
HK (2) HK1201292A1 (hr)
HR (5) HRP20191895T4 (hr)
HU (5) HUE046081T2 (hr)
IL (4) IL226727A (hr)
IN (1) IN2013CN07629A (hr)
LT (4) LT2738258T (hr)
ME (3) ME02106B (hr)
MX (2) MX343009B (hr)
MY (1) MY172713A (hr)
NZ (2) NZ776770A (hr)
PL (5) PL2578688T5 (hr)
PT (5) PT2578688T (hr)
RS (5) RS59413B2 (hr)
RU (2) RU2722373C2 (hr)
SG (4) SG192933A1 (hr)
SI (5) SI2738258T2 (hr)
SM (1) SMT201500061B (hr)
WO (1) WO2012141798A1 (hr)
ZA (1) ZA201305998B (hr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
PT2311874T (pt) 2004-07-22 2017-08-25 Univ Erasmus Med Ct Rotterdam Moléculas de ligação
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK3622813T3 (da) 2009-07-08 2021-05-03 Kymab Ltd Dyremodeller og terapeutiske molekyler
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
DE12192727T1 (de) 2011-02-25 2013-07-11 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
PT3572517T (pt) * 2011-08-05 2021-06-23 Regeneron Pharma Murganhos da cadeia leve universal humanizada
ES2612935T3 (es) * 2011-09-19 2017-05-19 Kymab Limited Anticuerpos, dominios variables y cadenas adaptados para su uso en seres humanos
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EP2763699A4 (en) 2011-10-03 2015-05-20 Univ Duke VACCINE
PL2627773T3 (pl) * 2011-10-17 2017-11-30 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši
ES2753774T3 (es) * 2012-02-01 2020-04-14 Regeneron Pharma Ratones humanizados que expresan cadenas pesadas que contienen dominios VL
RS57414B1 (sr) 2012-03-16 2018-09-28 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
BR112014022855A2 (pt) 2012-03-16 2017-07-18 Regeneron Pharma animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
CN104302170B (zh) 2012-03-16 2016-09-28 瑞泽恩制药公司 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
ME03551B (me) 2012-06-12 2020-07-20 Regeneron Pharma Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
EP2953452A1 (en) 2013-02-06 2015-12-16 Regeneron Pharmaceuticals, Inc. B cell lineage based immunogen design with humanized animals
WO2014130690A1 (en) * 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
ES2829376T3 (es) * 2013-03-14 2021-05-31 Univ Erasmus Med Ct Rotterdam Mamífero no humano transgénico para la producción de anticuerpos
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
KR102482103B1 (ko) 2016-01-13 2022-12-28 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
CN109195443A (zh) 2016-02-16 2019-01-11 雷杰纳荣制药公司 具有突变型犬尿氨酸酶基因的非人动物
RU2745563C2 (ru) * 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
KR102319069B1 (ko) 2016-11-04 2021-11-01 리제너론 파마슈티칼스 인코포레이티드 조작된 면역글로불린 람다 경쇄 유전자좌를 갖는 비인간 동물
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
PT3720279T (pt) 2017-12-05 2022-10-06 Regeneron Pharma Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos
CN112040769B (zh) 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP7477462B2 (ja) 2018-05-17 2024-05-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ６３抗体、コンジュゲート、及び、それらの使用
US20210230629A1 (en) * 2018-06-13 2021-07-29 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
KR102444180B1 (ko) 2018-06-14 2022-09-16 리제너론 파마슈티칼스 인코포레이티드 면역글로불린 중쇄 암호화 서열에서 dh-dh 재배열 가능한 비인간 동물
CN112400022B (zh) 2019-02-18 2023-06-30 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
TW202110323A (zh) 2019-06-05 2021-03-16 美商再生元醫藥公司 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途
DK3785536T3 (da) 2019-08-28 2022-03-28 Trianni Inc Adam6-knockin-mus
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
IL303626A (en) 2020-12-16 2023-08-01 Regeneron Pharma Mice expressing human FC alpha receptors
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
BR112023021256A2 (pt) 2021-04-20 2023-12-12 Regeneron Pharma Anticorpos humanos para artemina e métodos de uso dos mesmos
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
EP1183344A4 (en) * 1999-05-27 2003-06-25 Human Genome Sciences Inc ADAM POLYNUCLEOTIDES AND POLYPEPTIDES
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1632571B1 (en) 2001-05-11 2012-11-28 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome containing human antibody Lambda light chain and non-human animal containing the human artificial chromosome capable of genetic transmission
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
DE602005011421D1 (de) 2005-06-30 2009-01-15 Borealis Tech Oy Überzug-Schicht für Energie- oder Kommunikationskabel
AU2007235496B2 (en) * 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
MX2011007660A (es) * 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
DK3622813T3 (da) * 2009-07-08 2021-05-03 Kymab Ltd Dyremodeller og terapeutiske molekyler
DK2954779T3 (da) 2009-12-10 2019-05-13 Regeneron Pharma Mus, der frembringer tungkædeantistoffer
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
CN105695415A (zh) 2010-06-17 2016-06-22 科马布有限公司 动物模型及治疗分子
DE12192727T1 (de) 2011-02-25 2013-07-11 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
PT3572517T (pt) 2011-08-05 2021-06-23 Regeneron Pharma Murganhos da cadeia leve universal humanizada
PL2627773T3 (pl) 2011-10-17 2017-11-30 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
SI2793567T1 (sl) 2011-12-20 2019-05-31 Regeneron Pharmaceuticals, Inc. Humanizirane lahkoverižne miši

Also Published As

Publication number Publication date
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
IL268671B (en) 2020-05-31
DK2738258T1 (da) 2014-11-24
US20150210776A1 (en) 2015-07-30
CY1122820T1 (el) 2021-05-05
ES2748832T3 (es) 2020-03-18
SI2578688T2 (sl) 2023-05-31
US10905108B2 (en) 2021-02-02
BR112013021771B1 (pt) 2022-11-16
RS59413B1 (sr) 2019-11-29
US20180345760A1 (en) 2018-12-06
US20140213773A1 (en) 2014-07-31
RU2013125717A (ru) 2014-12-10
ES2748832T5 (es) 2023-06-08
RU2016109443A (ru) 2018-11-26
PL2738259T3 (pl) 2020-08-24
KR20130116375A (ko) 2013-10-23
CY1126091T1 (el) 2023-11-15
HRP20230526T1 (hr) 2023-09-01
HRP20191895T4 (hr) 2023-05-12
KR101387377B1 (ko) 2014-04-21
US8642835B2 (en) 2014-02-04
SG10201913160QA (en) 2020-03-30
EP2738258B1 (en) 2019-09-25
CY1116301T1 (el) 2017-02-08
US10577430B2 (en) 2020-03-03
ES2805364T3 (es) 2021-02-11
ME03732B (me) 2021-01-20
PL4067496T3 (pl) 2023-07-31
FI2578688T4 (fi) 2023-05-05
AU2022206806A1 (en) 2022-08-18
DK2738259T1 (da) 2014-11-24
CY1122459T1 (el) 2021-01-27
ME02106B (me) 2015-10-20
ZA201305998B (en) 2016-07-27
SI2738258T2 (sl) 2023-05-31
JP2022071051A (ja) 2022-05-13
HUE024534T2 (hu) 2016-01-28
DK4067496T3 (da) 2023-06-26
JP2019187446A (ja) 2019-10-31
EP2738258A2 (en) 2014-06-04
JP5866127B2 (ja) 2016-02-17
LT2578688T (lt) 2019-11-11
NZ731926A (en) 2021-07-30
EP2738259B1 (en) 2019-11-27
BR112013021771A2 (pt) 2017-07-04
HRP20200294T1 (hr) 2020-05-29
PL2578688T5 (pl) 2023-05-29
IL261243A (en) 2018-10-31
HRP20191895T1 (hr) 2020-01-10
JP2014507137A (ja) 2014-03-27
EP2550363B1 (en) 2014-12-10
SI2738258T1 (sl) 2020-01-31
ES2758974T5 (es) 2023-06-08
US20180346599A1 (en) 2018-12-06
DE14176593T1 (de) 2015-03-05
EP4067496B1 (en) 2023-03-29
EP2578688B1 (en) 2019-07-24
SI2578688T1 (sl) 2019-11-29
IL273986B (en) 2021-04-29
DK2550363T3 (en) 2015-03-23
DE12716101T1 (de) 2013-05-08
DK2813573T1 (da) 2015-01-12
US20180346598A1 (en) 2018-12-06
CN103429746A (zh) 2013-12-04
HK1174490A1 (en) 2013-06-14
MX343009B (es) 2016-10-21
AU2012243291B2 (en) 2015-07-09
WO2012141798A1 (en) 2012-10-18
DK2738258T4 (da) 2023-05-08
RS59929B1 (sr) 2020-03-31
EP2578688A1 (en) 2013-04-10
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
DK2578688T4 (da) 2023-05-08
FI2738258T4 (fi) 2023-05-05
IN2013CN07629A (hr) 2015-08-07
RU2582261C2 (ru) 2016-04-20
EP2738259A3 (en) 2014-07-30
CA2820824A1 (en) 2012-10-18
PL2738258T3 (pl) 2020-08-24
DE14154918T1 (de) 2014-08-21
PT2550363E (pt) 2015-03-16
HRP20150262T1 (hr) 2015-04-10
US9944716B2 (en) 2018-04-17
DK2578688T1 (da) 2014-11-24
CN103429746B (zh) 2016-05-11
DK2578688T3 (da) 2019-10-28
JP2014110814A (ja) 2014-06-19
SMT201500061B (it) 2015-05-05
ES2946169T3 (es) 2023-07-13
HK1201292A1 (en) 2015-08-28
DE14154967T1 (de) 2014-08-28
SG10201405135RA (en) 2014-10-30
EP2813573A1 (en) 2014-12-17
RU2016109443A3 (hr) 2019-07-24
AU2020201279A1 (en) 2020-03-12
RS64280B1 (sr) 2023-07-31
US20210105984A1 (en) 2021-04-15
US10905109B2 (en) 2021-02-02
PT2738259T (pt) 2020-02-18
PL2550363T3 (pl) 2015-05-29
MX2020009714A (es) 2020-10-07
LT4067496T (lt) 2023-06-12
EP3744850A1 (en) 2020-12-02
MX2013009649A (es) 2013-09-26
DK2738258T3 (da) 2019-12-16
US8697940B2 (en) 2014-04-15
US20210105985A1 (en) 2021-04-15
JP2018143250A (ja) 2018-09-20
ME03537B (hr) 2020-04-20
SI2738259T1 (sl) 2020-06-30
AU2012243291A1 (en) 2013-05-09
IL268671A (en) 2019-10-31
DE12192727T1 (de) 2013-07-11
US9932408B2 (en) 2018-04-03
ES2532487T3 (es) 2015-03-27
DK2738259T3 (da) 2020-02-17
JP2016135143A (ja) 2016-07-28
RU2722373C2 (ru) 2020-05-29
HRP20192311T1 (hr) 2020-03-20
US20130254911A1 (en) 2013-09-26
PT4067496T (pt) 2023-06-07
PL2578688T3 (pl) 2020-05-18
NZ703609A (en) 2016-04-29
RS53880B1 (en) 2015-08-31
EP2738258B2 (en) 2023-02-01
CN105861548A (zh) 2016-08-17
HUE046081T2 (hu) 2020-01-28
RS59413B2 (sr) 2023-06-30
EP4067496A1 (en) 2022-10-05
EP2738258A3 (en) 2014-09-24
US10694725B2 (en) 2020-06-30
IL261243B (en) 2019-08-29
NZ776770A (en) 2023-03-31
NZ718688A (en) 2017-07-28
US20150201589A1 (en) 2015-07-23
EP2550363A1 (en) 2013-01-30
IL226727A (en) 2016-08-31
LT2738259T (lt) 2020-03-10
SG10201913155QA (en) 2020-02-27
HUE046746T2 (hu) 2020-03-30
CN105861548B (zh) 2020-01-10
JP2015107131A (ja) 2015-06-11
PT2738258T (pt) 2019-12-10
EP2738259A2 (en) 2014-06-04
MY172713A (en) 2019-12-11
HUE062552T2 (hu) 2023-11-28
EP2578688B2 (en) 2023-02-08
RS59661B1 (sr) 2020-01-31
US20180362663A1 (en) 2018-12-20
US20120322108A1 (en) 2012-12-20
CY1122205T1 (el) 2020-11-25
ES2758974T3 (es) 2020-05-07
AU2015238806A1 (en) 2015-10-29
FI4067496T3 (fi) 2023-05-24
AU2017251802A1 (en) 2017-11-16
IL273986A (en) 2020-05-31
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
ES2770424T3 (es) 2020-07-01
RS59661B2 (sr) 2023-06-30
LT2738258T (lt) 2020-01-10
SI4067496T1 (sl) 2023-07-31
US10072095B2 (en) 2018-09-11
SG192933A1 (en) 2013-09-30
NZ612643A (en) 2015-06-26

Similar Documents

Publication Publication Date Title
HRP20192311T4 (hr) Adam6 miševi
HRP20192255T1 (hr) Humanizirani miševi s univerzalnim lakim lancem
HRP20210987T1 (hr) Humanizirani glodavci koji eksprimiraju teške lance koji sadrže vl domene
MX2019004871A (es) Animales no humanos humanizados con loci de cadena pesada de inmunoglobulina restringidos.
CY1123723T1 (el) Μη ανθρωπινα ζωα που φερουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 274
TR201903439T4 (tr) İnsanlaştırılmış hafif zincirli fareler.
JP2017534262A5 (hr)
CL2014001317A1 (es) Polipeptido aislado que tiene actividad de lisozima; polinucleotido aislado que lo codifica; construccion de acido nucleico o vector de expresion; celula huesped recombinante; metodo de produccion; composicion que lo comprende, ya sea detergente o de alimentacion animal o aditivo de alimentacion animal; y su uso.
WO2010056948A3 (en) Humanized anti-il-6 antibodies
EP4269430A3 (en) Non-human animals having a humanized signal-regulatory protein gene
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
EA202193165A1 (ru) Гаплоидный индуктор
BR112017021289A2 (pt) anticorpos anti-c1s humanizados e métodos de uso dos mesmos
BR112014015705A2 (pt) polipeptídeo isolado, composição, polinucleotídeo isolado,, construção de ácido nucleico ou vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo, para melhorar o valor nutritivo de uma ração parar animais e para o tratamento de proteínas, planta transgênica, parte de planta ou célula vegetal, uso de pelo menos um polipeptídeo, aditivo de ração para animal, ração para animais, e, composição detergente
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.
BR112014031882A2 (pt) uso de um polipeptídeo isolado, polipeptídeo, composição, polinucleotídeo isolado, construto de ácido nucleico ou vetor de expressão, célula hospedeira de expressão recombinante, métodos para produção de um polipeptídeo, para melhoria do valor nutricional de uma ração animal, e para o tratamento de proteínas, uso de pelo menos um polipeptídeo, aditivo de ração animal, ração animal, e, composição detergente
WO2015077538A3 (en) Nucleotide sequence encoding homeobox-leucine zipper protein hat22 (hd-zip protein 22) from corchorus olitorius and corchorus capsularis and methods of use
WO2015041924A3 (en) Recombinant respiratory syncytial virus (rsv) and caccines
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse
BR112014005708A2 (pt) polinucleotídeo isolado, construção de dna recombinante, vetor, célula, planta e semente transgênicas, métodos de expressão de sequência de codificação e de expressão de proteína fluorescente e método de alteração transgênica de características vegetais comercializáveis
EP3813520A4 (en) TRANSGENIC CHICKEN STABILIZING LONG CDR-H3S ANTIBODIES BY MEANS OF MULTIPLE DISULPHIDE BRIDGES AND DIVERSIFIED BY GENE CONVERSION
PL405607A1 (pl) Wyselekcjonowany szczep bakulowirusa LdMNPV-PL do zastosowań w produktach ochrony roślin, pełna lub częściowa sekwencja nukleotydowa lub aminokwasowa genów lub białek pochodząca ze szczepu bakulowirusa LdMNPV-PL
TH134762B (th) ส่วนสร้าง casb7439